Apigenin (4′,5,7-trihydroxyflavone) is a plant-derived flavonoid concentrated in chamomile flowers, parsley, celery, and several other common herbs. Beyond its well-characterized anxiolytic and anti-inflammatory properties, apigenin has attracted growing interest in oncology research — particularly for prostate cancer. A body of cell-based and animal studies suggests it can influence multiple molecular pathways involved in tumor cell survival, proliferation, and resistance to standard treatments.
The research discussed here is entirely preclinical, meaning it was conducted in cultured cell lines and rodent models rather than in human clinical trials. These findings establish biological plausibility and inform future research directions, but they do not demonstrate that apigenin prevents, treats, or cures prostate cancer in people. These statements have not been evaluated by the FDA. This article is informational only and does not constitute medical advice.
Key Takeaways
- Multiple preclinical studies show apigenin can induce apoptosis in both androgen-sensitive (LNCaP) and androgen-insensitive (PC-3) prostate cancer cell lines via mitochondrial and p21-dependent pathways [PMID 15486995, PMID 22065906].
- Apigenin inhibits prostate cancer cell cycle progression by modulating MAPK and PI3K-Akt signaling and suppressing cyclin D1, based on in vitro data [3].
- In TRAMP mouse models, apigenin supplementation significantly inhibited prostate cancer progression, implicating the PI3K/Akt/FoxO signaling axis [6].
- Early combination research suggests apigenin may sensitize prostate cancer stem cells to cisplatin and enhance the activity of abiraterone acetate in cell culture, though these are not clinical findings [PMID 28107698, PMID 35473536].
- All available evidence is preclinical; no human clinical trials have established apigenin as a treatment for prostate cancer, and it should not be used as a substitute for standard medical care.
Apoptosis: How Apigenin May Trigger Prostate Cancer Cell Death
One of the most consistently reported effects of apigenin in prostate cancer cell studies is its ability to induce apoptosis — programmed cell death. In androgen-sensitive LNCaP cells and androgen-insensitive PC-3 cells, apigenin promoted apoptosis partly by upregulating p21, a key cell cycle inhibitor, while transcriptionally suppressing polo-like kinase-1 (PLK1), an enzyme that supports cancer cell division [5].
A separate line of investigation focused on the mitochondrial pathway. In prostate epithelial cells, apigenin was found to drive the production of reactive oxygen species (ROS), which in turn triggered a mitochondria-mediated cell death cascade [1]. This is significant because the mitochondrial apoptosis pathway is frequently dysregulated in cancer cells as a survival mechanism, and compounds that can re-engage it are of considerable interest to researchers.
Cell Cycle Arrest: Disrupting Tumor Cell Proliferation
Beyond triggering cell death outright, apigenin has been shown to arrest the cell cycle — effectively halting the replication of cancer cells at specific checkpoints. In human prostate cancer cells, this arrest was associated with modulation of both the MAPK and PI3K-Akt signaling pathways, as well as a loss of cyclin D1 linked to retinoblastoma protein dephosphorylation [3]. Cyclin D1 is a protein that normally drives cells from the G1 phase into active DNA replication; its suppression is one mechanism by which cancer cell multiplication can be interrupted.
This multi-pathway disruption is notable because prostate cancer cells — particularly those that have progressed to castration-resistant states — often rewire signaling networks to bypass single-target interventions. Apigenin’s apparent ability to act on several nodes simultaneously may partly explain why it retains activity across both androgen-sensitive and androgen-insensitive cell lines in laboratory settings.
PI3K/Akt/FoxO Signaling: In Vivo Evidence from Animal Models
Cell culture studies are a necessary first step, but animal model data provides a more integrated picture of how a compound behaves in a living system. The TRAMP (transgenic adenocarcinoma of the mouse prostate) mouse is a well-validated preclinical model of spontaneous prostate cancer progression. In one study, apigenin supplementation significantly inhibited prostate cancer progression in TRAMP mice, with the researchers identifying the PI3K/Akt/FoxO signaling axis as a key mechanistic target [6].
The FoxO transcription factors regulated downstream of PI3K/Akt are involved in controlling cell cycle arrest, apoptosis, and DNA repair. When the PI3K/Akt pathway is overactive — as it commonly is in prostate tumors — FoxO proteins are phosphorylated and exported from the nucleus, reducing their tumor-suppressive activity. Apigenin’s modulation of this pathway in the TRAMP model offers a plausible proposed mechanism for the in vivo tumor-inhibitory effects observed, though direct translation to human outcomes remains unproven.
Androgen Receptor Signaling and Castration-Resistant Prostate Cancer
Prostate cancer growth is typically driven by androgen signaling through the androgen receptor (AR). Standard androgen deprivation therapy initially controls most prostate cancers, but a significant proportion progress to castration-resistant prostate cancer (CRPC), a stage associated with limited treatment options [8]. Research into natural compounds that can modulate AR activity or overcome resistance mechanisms has therefore attracted substantial scientific interest.
Phytoestrogens including apigenin have been shown to regulate prostate cancer cell growth in vitro by interacting with hormonal signaling pathways [2]. Apigenin-rich extracts of Wedelia chinensis demonstrated the ability to attenuate AR activity and reduce orthotopic tumor growth in nude mice [4]; a standardized version of this extract was also shown to overcome feedback activation of HER2/3 signaling that commonly occurs after androgen ablation [10]. Natural products including apigenin have been reviewed as part of emerging strategies for managing CRPC, with nanoparticle-based delivery systems under investigation to address poor bioavailability [11].
A combination study found that apigenin used alongside abiraterone acetate — a standard drug for castration-sensitive prostate cancer — attenuated the survival of human castration-sensitive prostate cancer cells to a greater degree than abiraterone alone in cell culture [12]. This type of synergy research remains early stage, but it illustrates why researchers are exploring apigenin as a potential adjunct rather than a standalone agent.
Glucose Metabolism: Disrupting Cancer Cell Energy Supply
A mechanistically interesting area involves apigenin’s effects on glucose transport in prostate cancer cells. Cancer cells rely heavily on glucose uptake — a phenomenon called the Warburg effect — and overexpress glucose transporter (GLUT) proteins to sustain this demand. Research examining both androgen-sensitive and androgen-insensitive prostate cancer cells found that flavonoids including apigenin can regulate GLUT transporter expression [7], potentially reducing a cancer cell’s ability to fuel rapid growth.
This metabolic angle complements the pathway-level mechanisms described above and adds another dimension to apigenin’s multi-target profile observed in laboratory research. Whether this translates into meaningful metabolic effects in human tumors is not yet known.
Prostate Cancer Stem Cells and Chemotherapy Sensitization
Cancer stem cells represent a subpopulation of tumor cells with enhanced self-renewal capacity and resistance to conventional therapies, and they are recognized as drivers of treatment failure and relapse. In prostate cancer, CD44-positive cells are considered to carry stem-cell-like properties. One study found that apigenin sensitized human CD44+ prostate cancer stem cells to cisplatin therapy, a standard chemotherapeutic agent [9].
This sensitization effect addresses one of the core challenges in oncology: making resistant cancer cells more vulnerable to existing treatments. If apigenin can lower the threshold at which cancer stem cells respond to chemotherapy, it could in principle improve outcomes when used in combination — though this hypothesis remains entirely untested in clinical settings and should not be interpreted as a treatment recommendation.
🛒 Where to Buy Apigenin
- Momentous Momentous ApigeninLab-tested / studied
capsules, 50 mg per capsule — Andrew Huberman’s publicly recommended brand; NSF Certified for Sport; single-ingredient, no fillers - Double Wood Supplements Apigenin 50mg
capsules, 50 mg per capsule, 120 count — High-volume value pick; third-party tested for purity; frequently top-ranked on Amazon - Nutricost Apigenin 50mg
capsules, 50 mg per capsule, 120 count — FDA-registered facility; gluten-free, non-GMO; competitive price-per-dose - Swanson Apigenin 50mg
capsules, 50 mg per capsule, 90 count — Established supplement brand; GMP-certified manufacturing; widely available, low cost
As an Amazon Associate we earn from qualifying purchases. Shilajit quality varies widely — always choose a product with a published third-party heavy-metal test (COA) before buying.
A Note on the Evidence
All research cited here is preclinical (cell culture and animal models); no human clinical trials have established apigenin as effective for prostate cancer prevention or treatment, and it must not replace standard oncology care. Apigenin inhibits CYP1A2, CYP2C9, and CYP3A4, meaning individuals on prostate cancer drugs including abiraterone, anticoagulants, certain statins, or benzodiazepines face a real risk of drug interactions and should consult their physician before use.
Frequently Asked Questions
What is apigenin and where does it come from?
Apigenin is a plant flavonoid (4′,5,7-trihydroxyflavone) found in high concentrations in chamomile flowers, parsley, celery, and several other herbs and vegetables. It has been studied for anxiolytic, anti-inflammatory, and — in preclinical settings — potential anti-tumor properties. It binds benzodiazepine receptor sites on GABA-A receptors and inhibits cyclin-dependent kinases involved in cell proliferation.
Does apigenin kill prostate cancer cells in laboratory studies?
In cell culture research, apigenin has been shown to induce apoptosis in human prostate cancer cell lines, including both androgen-sensitive LNCaP and androgen-insensitive PC-3 cells, acting through p21 upregulation and PLK1 suppression [5] and by triggering mitochondria-mediated cell death via reactive oxygen species [1]. These are cell culture findings and do not confirm the same effects occur in the human body.
Has apigenin been tested in animal models of prostate cancer?
Yes. At least one study using the TRAMP mouse model of spontaneous prostate cancer found that apigenin significantly inhibited tumor progression, with effects attributed to targeting the PI3K/Akt/FoxO signaling pathway [6]. Animal model results do not reliably predict outcomes in human clinical trials, so these findings should be interpreted with appropriate caution.
Could apigenin be relevant to castration-resistant prostate cancer?
Preclinical research suggests apigenin and apigenin-rich plant extracts may modulate androgen receptor activity and counteract some resistance mechanisms seen in CRPC, including HER2/3 feedback activation following androgen ablation [10]. Natural products including apigenin are under investigation in this context, including nanoparticle-based delivery approaches to improve absorption [11]. No clinical evidence in humans currently supports using apigenin for CRPC.
Is it safe to take apigenin alongside prostate cancer medication?
This question requires a physician’s guidance, not a supplement article. Apigenin inhibits CYP1A2, CYP2C9, and CYP3A4 liver enzymes that metabolize many drugs, including abiraterone acetate — a common prostate cancer drug that was studied in combination with apigenin in cell research [12]. Drug interactions are a genuine concern, and anyone currently on prostate cancer treatment must consult their oncologist before adding any supplement.
What is the significance of apigenin's effect on CD44+ prostate cancer stem cells?
Cancer stem cells expressing CD44 are associated with treatment resistance and disease recurrence. One cell line study found that apigenin sensitized CD44+ prostate cancer stem cells to cisplatin, suggesting it may help overcome a key mechanism of chemotherapy resistance [9]. This is a single preclinical finding in cultured cells; it does not demonstrate clinical benefit and should not influence treatment decisions without guidance from an oncologist.
References
- Morrissey C et al. Apigenin drives the production of reactive oxygen species and initiates a mitochondrial mediated cell death pathway in prostate epithelial cells. The Prostate (2005). PMID 15486995
- Shenouda NS et al. Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutrition and cancer (2004). PMID 15489213
- Shukla S et al. Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell cycle (Georgetown, Tex.) (2007). PMID 17457054
- Tsai CH et al. Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID 19690196
- Seo YJ et al. Apoptotic effects of genistein, biochanin-A and apigenin on LNCaP and PC-3 cells by p21 through transcriptional inhibition of polo-like kinase-1. Journal of Korean medical science (2011). PMID 22065906
- Shukla S et al. Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway. Carcinogenesis (2014). PMID 24067903
- Gonzalez-Menendez P et al. Regulation of GLUT transporters by flavonoids in androgen-sensitive and -insensitive prostate cancer cells. Endocrinology (2014). PMID 24932809
- Armstrong CM et al. Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. American journal of clinical and experimental urology (2015). PMID 26309896
- Erdogan S et al. The natural flavonoid apigenin sensitizes human CD44(+) prostate cancer stem cells to cisplatin therapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2017). PMID 28107698
- Tsai CH et al. A Standardized Wedelia chinensis Extract Overcomes the Feedback Activation of HER2/3 Signaling upon Androgen-Ablation in Prostate Cancer. Frontiers in pharmacology (2017). PMID 29066975
- Singla RK et al. Natural Products for the Management of Castration-Resistant Prostate Cancer: Special Focus on Nanoparticles Based Studies. Frontiers in cell and developmental biology (2021). PMID 34805155
- Genc F et al. Abiraterone Acetate, in Combination with Apigenin, Attenuates the Survival of Human Castration-Sensitive Prostate Cancer Cells. Anti-cancer agents in medicinal chemistry (2022). PMID 35473536
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
